{"entity":{"id":"nct07787429","kind":"trial","name":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma","aka":[],"tldr":"A phase 2 trial of Mifamurtide and Sorafenib in Osteosarcoma, run by Anna Raciborska, now recruiting.","summary":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma is a phase 2 interventional study registered as NCT07787429 by Anna Raciborska, with 40 participants planned, started 2026-04-01 and due to reach its primary completion in 2033-07-31. Interventions recorded: Mifamurtide, Sorafenib. Conditions recorded: Osteosarcoma.\n\nLinked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07787429","url":"https://clinicaltrials.gov/study/NCT07787429"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mifamurtide","sorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07787429","phase":"2","setting":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma (DRAGONFLY)","sponsor":"Anna Raciborska","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07787429/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/"},{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/"}]}}